File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and network meta-analysis of randomised controlled trials

TitleOptimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and network meta-analysis of randomised controlled trials
Authors
Issue Date2017
PublisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinthera
Citation
The 13th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Prague, Czech Republic, 24-27 June 2017. In Clinical Therapeutics, 2017, v. 39 n. 8S, p. e49 How to Cite?
AbstractBackground The optimal duration of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent (DES) implantation remains uncertain. Despite recent studies, direct comparison between short-term (<12 months) and extended (>12 months) DAPT is limited. We performed a network meta-analysis to assess the risk of mortality and other cardiovascular outcomes with different DAPT durations in order to guide clinical practice. Methods We searched for randomised controlled trials comparing different durations of DAPT after DES implantation. Those reporting frequencies of cardiovascular and bleeding events were eligible to be included. Statistic analysis was performed using frequentist approach and Bayesian framework in R. Results We included 12 randomised controlled trials with altogether 34920 patients for analysis. Extended DAPT (>12 months) significantly lowered the risk of myocardial infarction (OR 0.56, 95%CI 0.46-0.68 and 0.58, 0.44-0.77), and stent thrombosis (0.44, 0.30-0.65 and 0.49, 0.29-0.82) when compared to 12-month and short-term DAPT (<12 months), respectively. However, it was associated with increased major bleeding (1.53, 1.21-1.93 and 2.58, 1.62-4.10). Compared to 12-month DAPT, extended DAPT had more all-cause death (1.27, 1.03-1.57); short-term DAPT had less major bleeds (0.59, 0.39-0.91). Conclusions Although extending DAPT beyond 12 months after DES implantation reduced myocardial infarction and stent thrombosis, the risk of major bleeding and all-cause mortality was substantially increased. No clear superiority of extended or short-term DAPT over 12-month DAPT was identified. DAPT duration should always be tailored for different patients after considering their benefit-risk profiles.
Persistent Identifierhttp://hdl.handle.net/10722/247884
ISSN
2017 Impact Factor: 3.185
2015 SCImago Journal Rankings: 0.997

 

DC FieldValueLanguage
dc.contributor.authorFei, Y-
dc.contributor.authorTsoi, MF-
dc.contributor.authorCheung, TT-
dc.contributor.authorCheung, BMY-
dc.date.accessioned2017-10-18T08:34:13Z-
dc.date.available2017-10-18T08:34:13Z-
dc.date.issued2017-
dc.identifier.citationThe 13th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Prague, Czech Republic, 24-27 June 2017. In Clinical Therapeutics, 2017, v. 39 n. 8S, p. e49-
dc.identifier.issn0149-2918-
dc.identifier.urihttp://hdl.handle.net/10722/247884-
dc.description.abstractBackground The optimal duration of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent (DES) implantation remains uncertain. Despite recent studies, direct comparison between short-term (<12 months) and extended (>12 months) DAPT is limited. We performed a network meta-analysis to assess the risk of mortality and other cardiovascular outcomes with different DAPT durations in order to guide clinical practice. Methods We searched for randomised controlled trials comparing different durations of DAPT after DES implantation. Those reporting frequencies of cardiovascular and bleeding events were eligible to be included. Statistic analysis was performed using frequentist approach and Bayesian framework in R. Results We included 12 randomised controlled trials with altogether 34920 patients for analysis. Extended DAPT (>12 months) significantly lowered the risk of myocardial infarction (OR 0.56, 95%CI 0.46-0.68 and 0.58, 0.44-0.77), and stent thrombosis (0.44, 0.30-0.65 and 0.49, 0.29-0.82) when compared to 12-month and short-term DAPT (<12 months), respectively. However, it was associated with increased major bleeding (1.53, 1.21-1.93 and 2.58, 1.62-4.10). Compared to 12-month DAPT, extended DAPT had more all-cause death (1.27, 1.03-1.57); short-term DAPT had less major bleeds (0.59, 0.39-0.91). Conclusions Although extending DAPT beyond 12 months after DES implantation reduced myocardial infarction and stent thrombosis, the risk of major bleeding and all-cause mortality was substantially increased. No clear superiority of extended or short-term DAPT over 12-month DAPT was identified. DAPT duration should always be tailored for different patients after considering their benefit-risk profiles.-
dc.languageeng-
dc.publisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinthera-
dc.relation.ispartofClinical Therapeutics-
dc.rightsPosting accepted manuscript (postprint): © <year>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titleOptimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and network meta-analysis of randomised controlled trials-
dc.typeConference_Paper-
dc.identifier.emailCheung, TT: tcheungt@hku.hk-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.authorityCheung, TT=rp01682-
dc.identifier.authorityCheung, BMY=rp01321-
dc.identifier.doi10.1016/j.clinthera.2017.05.152-
dc.identifier.hkuros282104-
dc.identifier.volume39-
dc.identifier.issue8S-
dc.identifier.spagee49-
dc.identifier.epagee49-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats